RT Journal Article
SR Electronic
T1 Limits of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 694
OP 697
DO 10.1111/IGC.0b013e3181da2912
VO 20
IS 5
A1 Margherita Giorgini
A1 Claudia Marchetti
A1 Violante Di Donato
A1 Jacopo Tesei
A1 Natalina Manci
A1 Pierluigi Benedetti Panici
YR 2010
UL http://ijgc.bmj.com/content/20/5/694.abstract
AB Most borderline ovarian tumors (BOT) occur in young women and exhibit a low malignant behavior. Nevertheless, an accurate long-term follow-up is required because, frequently, recurrence arises after many years from primary treatment, especially in patients affected by BOT with invasive peritoneal implants, which have a worse prognosis. We report the case of a pelvic recurrence of serous BOT firstly suspected by physical examination but misdiagnosed by 18F-fluorodeoxyglucose positron emission tomography and computed tomography and identified only by magnetic resonance imaging, 7 years after primary treatment. We also reviewed the literature concerning the role of 18F-fluorodeoxyglucose positron emission tomography in the management and follow-up of BOT.